High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis

J Thorac Oncol. 2013 Jun;8(6):711-8. doi: 10.1097/JTO.0b013e3182897c14.

Abstract

Introduction: Infection with high-risk types of human papillomavirus (hrHPV) is associated with cervical, anogenital, and oropharyngeal cancers. Since a causal contribution of hrHPV infection to lung cancer (LC) is still a matter of debate, a comprehensive study was performed to delineate hrHPV involvement in LC, using a Dutch study population.

Methods: Archival tissue specimens from 223 patients (145 men, 78 women, median age 65 years, range 27-87 years), who presented with cancer in the lungs, were subjected to GP5+/6+ polymerase chain reaction and p16 immunohistochemistry. The series included primary lung carcinomas of patients without a history of cancer (n = 175), primary lung carcinomas of patients with an unrelated cancer in the past (n = 36), and carcinomas with primary presentation in the lungs of which the origin (i.e., primary or metastasis) was equivocal at the time of diagnosis (n = 12). GP5+/6+ polymerase chain reaction/p16 double-positive carcinomas were subjected to HPV genotyping, HPVE7 transcript analysis, loss of heterozygosity analysis, and array-comparative genomic hybridization.

Results: Whereas all primary lung carcinomas were hrHPV-negative (211 of 211, 100%), three hrHPV-positive equivocal carcinomas (3 of 12, 25%) were identified. These patients (1 male, 2 females) had a history of hrHPV-associated disease; one tonsillar and two cervical carcinomas. A clonal relationship between individual tumor pairs was supported by identical hrHPV genotype, pattern of p16 expression, HPVE7 mRNA expression, and genomic aberrations.

Conclusions: hrHPV presence in a tumor with primary presentation in the lungs signifies pulmonary metastasis from a primary hrHPV-positive cancer elsewhere in the body. No support was found for an attribution of hrHPV infection to the development of primary LC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / secondary*
  • Adenocarcinoma / virology
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Large Cell / genetics
  • Carcinoma, Large Cell / secondary*
  • Carcinoma, Large Cell / virology
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / secondary*
  • Carcinoma, Non-Small-Cell Lung / virology
  • Carcinoma, Squamous Cell / genetics
  • Carcinoma, Squamous Cell / secondary*
  • Carcinoma, Squamous Cell / virology
  • Comparative Genomic Hybridization
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • DNA, Viral / genetics
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Loss of Heterozygosity
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / virology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Papillomaviridae / genetics
  • Papillomavirus Infections / genetics
  • Papillomavirus Infections / pathology*
  • Papillomavirus Infections / virology
  • Polymerase Chain Reaction
  • Prognosis
  • RNA, Messenger / genetics
  • RNA, Viral / genetics
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Risk Factors

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • DNA, Viral
  • RNA, Messenger
  • RNA, Viral